MedTrace Logo

A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease

NCT02663908 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 545

Last updated 2022-06-29

Study results available
· View outcomes & findings →

Summary

The purpose of this trial is to test if a marketed drug for advanced prostate cancer (FIRMAGON) can reduce the risk of cardiovascular complications as compared to another marketed drug for advanced prostate cancer (LUPRON DEPOT) in subjects with prostate cancer and cardiovascular disease.

Conditions

Interventions

DRUG

Degarelix

DRUG

Leuprolide

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Compliance · Ferring Pharmaceuticals

  • Susan Slovin, MD · Sidney Kimmel Center for Urologic and Prostate Cancers, Memorial Sloan Kettering Cancer Center

  • John Alexander, MD, MHS · Division of Cardiovascular Medicine, Duke Clinical Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-19
Primary Completion
2021-03-29
Completion
2021-03-29

Countries

  • United States
  • Canada
  • Czechia
  • Finland
  • France
  • Germany
  • Greece
  • Poland
  • Russia
  • Slovakia
  • South Africa
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02663908 on ClinicalTrials.gov